Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...
CRISPR’s use has vast potential in basic research to add to the understanding of cellular activity and in healthcare for precision therapies for today’s untreatable diseases. To date, some 30 clinical ...
Editas Medicine may have been first to enter the clinic with a gene-editing therapy, but it was beaten to the finish line by Intellia with first-in-human results in June. But it’s not a competition.
Editas Medicine released a tiny drop of data last year as a proof of concept for its gene editing platform. Now, the CRISPR/Cas9 biotech will spend 2022 trying to back that up. We’re going to hear ...
Editas Medicine said today its lead candidate EDIT-101, an in vivo CRISPR gene editing treatment for Leber congenital amaurosis-10 (LCA10), showed positive initial clinical data showing it to be safe, ...
Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...
Intellia Therapeutics (NASDAQ:NTLA) fell ~9% in the pre-market on Thursday after the biotech announced data from an ongoing Phase 2 trial for NTLA-2002, a CRISPR-based gene editing therapy for an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results